ClinVar Miner

Submissions for variant NM_015102.5(NPHP4):c.910G>A (p.Val304Ile)

gnomAD frequency: 0.00002  dbSNP: rs571395593
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001931098 SCV002196632 uncertain significance Nephronophthisis 2024-01-24 criteria provided, single submitter clinical testing This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 304 of the NPHP4 protein (p.Val304Ile). This variant is present in population databases (rs571395593, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with NPHP4-related conditions. ClinVar contains an entry for this variant (Variation ID: 1419053). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on NPHP4 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Fulgent Genetics, Fulgent Genetics RCV002507046 SCV002802052 uncertain significance Nephronophthisis 4; Senior-Loken syndrome 4 2022-05-05 criteria provided, single submitter clinical testing
Ambry Genetics RCV003348630 SCV004068471 uncertain significance Inborn genetic diseases 2023-06-30 criteria provided, single submitter clinical testing The c.910G>A (p.V304I) alteration is located in exon 8 (coding exon 7) of the NPHP4 gene. This alteration results from a G to A substitution at nucleotide position 910, causing the valine (V) at amino acid position 304 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.